INSM
INSM
$109.38
per share, on-chain
What INSM does
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
- Industry
- Healthcare
- CEO
- William H. Lewis
- Website
- insmed.com
Ways to own INSM
There's one version of this stock on Firstshare.
OndoINSMonOur pick
Wider choice. Usually $20 minimum, and it can cost more when New York is closed.
Daily backing report (29 Oct) ↗Monthly backing report (Sep 2026) ↗
$109.38
Closed until New York opens
Price check
What a slice looks like
$10.00 buys you 0.091 of one INSM share.
That's 9.1% of one share. Small, but it's yours, and it moves with the real price. One share costs $109.38.